Chemical Properties:
Package: Fluorinated Bottle, 25kg/Drum, or according to customer's requirement Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moistureShanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of (R)-1-Boc-3-Aminopiperidine (CAS: 188111-79-7) with high quality, commercial production. Ruifu Chemical offers a wide range of chiral compounds. We can provide Certificate of Analysis (COA), worldwide delivery, small and bulk quantities available. Please contact: alvin@ruifuchem.com| Item | Specifications |
| Appearance | Colorless to Yellow Liquid or Solid |
| Water Content (K.F) | <0.50% |
| Purity / Analysis Method | >99.5% (GC) |
| e.e | >99.5% |
| Specific Rotation [α]20/D | -30.5° ~ -26.5° (C=1 in DMF) |
| Infrared Spectrum | Conforms to Structure |
| NMR | Conforms to Structure |
| Test Standard | Enterprise Standard |
| Usage | Chiral Compounds; Pharmaceutical Intermediates |
Description:
Specifications:
Package & Storage:
| Chemical Name | (R)-1-Boc-3-Aminopiperidine |
| Synonyms | (R)-(-)-3-Amino-1-Boc-Piperidine; (R)-1-Boc-3-Piperidinamine; tert-Butyl (R)-3-Amino-1-Piperidinecarboxylate |
| CAS Number | 188111-79-7 |
| CAT Number | RF-CC348 |
| Stock Status | In Stock, Production Scale Up to Tons |
| Molecular Formula | C10H20N2O2 |
| Molecular Weight | 200.28 |
| Density | 1.041±0.060 g/cm3 |
| Refractive Index | 1.473 |
| Water Solubility | Immiscible With Water |
| Brand | Ruifu Chemical |
Advantages:
FAQ:
Application:
(R)-1-Boc-3-Aminopiperidine (CAS: 188111-79-7) is used as an intermediate in the manufacture of various substances such as pharmaceuticals. (R)-1-Boc-3-Aminopiperidine can be used as a precursor for the preparation of dipeptidyl peptidase IV inhibitors like API (CAS:361442-04-8), Linagliptin (CAS: 668270-12-0), Alogliptin (CAS: 850649-61-5), and other antidiabetic agents. (CAS: 361442-04-8) is a type 2 diabetes drug that can stimulate the pancreas to produce more insulin after the meal. It was reached by the cooperation of AstraZeneca and Bristol-Myers Squibb Company and belongs to DPP-IV inhibitor. It plays the role through inhibiting GLP-l degradation. GLP-I is the hormones naturally produced in the intestine after taking food. (CAS:361442-04-8) can regulate the secretion of insulin and strengthen the utilization of glucose in the peripheral tissues. The single medication of (CAS:361442-04-8) improve blood glucose control and the combined medication of (CAS:361442-04-8) with metformin, sulfonylurea and thiazolidinediones can enhance curative effect. It leads to low risk of hypoglycemia and its adverse reactions are similar to placebo, showing better tolerance.
